Anti-EMSY polyclonal antibody in lung cancer research

Article: "EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion"

Lung cancer: deregulation of the ubiquitin-proteasome system promotes suppression of innate immunity, which fosters lung cancer immune evasion.

In a new study, Marzio et al. (Cell, 2022) show that KEAP1 targets the transcriptional repressor EMSY for ubiquitin-mediated degradation to regulate homologous recombination repair and anti-tumor immunity in lung cancer.

The anti-EMSY HPA050777 (BRCA2 interacting transcriptional repressor) polyclonal antibody from Atlas Antibodies was used in the study.

Read full article here.

Find out more about our anti-EMSY polyclonal antibody.